Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$3.59 USD
-0.16 (-4.27%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $3.60 +0.01 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AUTL 3.59 -0.16(-4.27%)
Will AUTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUTL
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Other News for AUTL
Syncona net asset value down 5% reflecting fall in Autolus share price
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript
Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials
Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial
Positive Outlook for Autolus Therapeutics with Upcoming Obe-cel Approvals and Promising Clinical Trials